Background Decreases in circulating neutrophils (polymorphonuclear leucocytes, PMNs) have been reported in patients treated with the anti-interleukin-6 receptor (IL-6R) antibody tocilizumab (TCZ); the mechanism for this is unclear. We hypothesize that TCZ reduces circulating neutrophils by affecting margination and/or bone marrow trafficking without affecting neutrophil function or apoptosis.
Introduction
Interleukin-6 (IL-6) is a pleiotropic cytokine with a central role in the pathogenesis of a number of inflammatory and autoimmune disorders [1] . Neutrophils (polymorphonuclear leucocytes, PMNs) are involved in many inflammatory diseases, in part through the release of cytokines and chemokines, and through antigen presentation [2] . Activated neutrophils are a source of soluble interleukin-6 receptor (sIL-6R), initiating 'trans-signalling' in cell types that do not express membrane-bound IL-6R (mIL-6R), thus driving chronic inflammation [3] [4] [5] .
Tocilizumab (TCZ), a humanized monoclonal antibody against both forms of the IL-6R, is licensed for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis and polyarticular juvenile idiopathic arthritis [6] [7] [8] . Decreases in circulating neutrophil levels have been reported after initiation of TCZ in clinical trials. Despite this, the rate of serious infections is low (4Á7 per 100 patient-years) [9] , and no temporal association has been described between decreased neutrophil counts and the occurrence of such infections [6] [7] [8] [9] [10] .
Data from animal studies on the effects of IL-6 on neutrophil function have, to date, been inconsistent. IL-6 administration in rabbits results in reduced expression of surface CD62L on circulating and bone marrow neutrophils [11] . IL-6 administration in monkeys, however, results in reduced expression of CD162 while CD11b and CD62L expression is unchanged; this process is inhibited by TCZ [12] . In humans, in vitro exposure of healthy neutrophils to IL-6 does not affect neutrophil survival or functional capacity [13] , although additional lipopolysaccharide (LPS) stimulation following TCZ exposure in vitro has been reported to result in differences in oxidative burst and phagocytic capacity under hypoxic conditions [14] . Studies on neutrophils isolated from patients with rheumatoid arthritis 28 days after administration of TCZ, however, show no effect on neutrophil function or apoptosis [13] .
Administration of recombinant human IL-6 in rats [15] and rabbits [16] results in a biphasic blood neutrophilia, with an early peak resulting from leucocyte mobilization from the intravascular marginated pool, and a late peak due to neutrophil release from the postmitotic bone marrow pool. IL-6 contributes to granulopoiesis in granulocyte colony-stimulating factor (G-CSF)-and granulocyte-macrophage colony-stimulating factor (GM-CSF)-deficient mice [17] . In humans, strenuous exercise similarly causes a biphasic neutrophilia [18] that has been shown to correlate with an increase in serum IL-6 [19] , although this correlation has not been replicated in all studies [20] .
Broader aspects of neutrophil function and apoptosis at the expected neutrophil nadir 4 days following TCZ administration have not been assessed, and no studies have been undertaken to examine the effects of IL-6 modulation on in vivo whole body neutrophil kinetics in humans. Likewise, to date, there is no mechanistic understanding of the decrease in circulating neutrophils following treatment with TCZ. Such data are also required to comply with European Medicines Agency requests on providing further safety information on the use of TCZ. Therefore, an exploratory study was conducted in healthy subjects to investigate the hypothesis that IL-6R blockade affects whole body neutrophil kinetics by affecting neutrophil margination and/or re-uptake by the bone marrow, without affecting neutrophil function and survival.
Methods

Study subjects
This single-blind, randomized study (ClinicalTrials.gov identifier NCT01991990) enrolled healthy male subjects aged 18-65 years. Subjects had a body mass index between 18 and 30 kg/m 2 , were nonsmokers and did not receive any medication other than paracetamol. The study was approved by the East Midlands Nottingham Research Ethics Committee (Reference 13/EM/0350). All subjects provided written informed consent in accordance with the Declaration of Helsinki and local laws and regulations.
Study design
Subjects were randomized to receive a single intravenous dose, blinded to subjects only, of TCZ 8 mg/kg or saline placebo (2 : 1 randomization) on day 0 (Fig. 1a) . No subjects experienced clinically significant Common Terminology Criteria (CTC) grade 3 or 4 neutropenia (neutrophil count below 1 9 10 9 /L). However, there was a wide variation in the relative reduction in blood neutrophil count following TCZ; therefore, in the analysis, TCZ-treated subjects were divided into two equal-sized groups to examine the effects of IL-6R blockade based on the extent of the decrease in their neutrophil count. This grouping was result driven and not predefined.
Neutrophil isolation
Neutrophils were isolated from peripheral blood using dextran sedimentation and discontinuous plasma-Percoll (Fisher Scientific, Loughborough, UK) gradient centrifugation, as previously described [21] .
Neutrophil function and apoptosis ex vivo
Neutrophil function and apoptosis were assessed ex vivo on day 0 (pre-dose) and day 4 (post-dose). Respiratory burst was measured in neutrophils, primed with tumour necrosis factoralpha (TNFa, 20 ng/mL; R&D, UK) or phosphate-buffered saline (PBS) control for 30 min, as the peak in N-formylmethionyl-leucyl-phenylalanine (fMLP; Sigma-Aldrich, UK)-stimulated, horseradish peroxidase (HRP; Sigma-Aldrich, UK)-catalyzed luminol (Sigma-Aldrich, UK) chemiluminescence [22] . Phagocytosis was assessed in neutrophils equilibrated at 4°C or 37°C for 1 h followed by addition of heat-killed, eFluor670 (eBioscience, UK)-labelled Streptococcus pneumoniae (ratio 1 PMN : 29 S. pneumoniae) for 1 h, and quantified by flow cytometry [23] . For assessment of apoptosis, neutrophils were incubated for 20 h with vehicle control or a pro-survival factor, either GM-CSF (1 ng/mL; R&D, UK) or TNFa (20 ng/mL), and apoptosis was quantified by annexin V-FITC and propidium iodide (PI) (BD Biosciences, UK) staining, with early apoptotic cells being annexin V + /PI -and late apoptotic cells annexin V + /PI + .
Cytospin slides were also generated and stained with Diff-Quik staining (Gamidor, UK), and neutrophil morphology examined in a minimum of 300 neutrophils per slide using oil immersion light microscopy with the assessor blinded to treatment conditions. Apoptotic cells were identified by their darkly stained, pyknotic nuclei [24] . Surface markers were measured in fresh (0 min), PBS control (30 min) and fMLP-stimulated (30 min) neutrophils incubated for 30 min with the anti-human antibodies CD11b-BV421, CD16-FITC, CD62L-APC and CD162-PE, or isotype controls (BD Biosciences, UK). Expressions were quantified as median fluorescence intensities (MFI) by flow cytometry. Shape change was assessed by median forward scatter (FSC). Data were analysed using FlowJo software.
Neutrophil kinetics in vivo
Autologous neutrophils were isolated from peripheral blood by Hetastarch (Grifols, UK) sedimentation and discontinuous plasma-Percoll gradient centrifugation. Neutrophils were harvested and labelled with indium-111 ( 111 In; Mallinckrodt, UK) chelated to tropolone (Ipswich Pharmacy Manufacturing Unit, UK) by incubation at room temperature for 10 min, subsequently washed twice in platelet-poor plasma and re-injected (maximum 2Á5 MBq) into the subjects [25, 26] . Blood was sampled 45 min post-re-injection to determine the percentage recovery of radiolabelled neutrophils, as previously described [26] . Longitudinal whole body profiles were generated in a fully shielded whole body gamma-counter at 45 min (day 4), 1 day (day 5) and 6 days (day 10) following re-injection. For each scan, the collimated anterior and posterior detectors moved from head downwards at 14 cm/min for 10 min (Fig. 5a ). Counts were background and decay corrected, and geometric means normalized to day 4 counts.
Safety
Safety was assessed by physical examination, vital signs and monitoring of adverse events and laboratory parameters. All subjects completed all study and safety visits.
Statistical analysis
All ex vivo assays were performed in triplicate. Data are presented as mean AE SEM of (n) independent experiments and analysed using GraphPad Prism version 6. Treatment groups were compared using one-way ANOVA and unpaired t-tests with Holm-Sidak correction for multiple comparisons.
Results
Study subjects
A total of 18 subjects were treated with a single intravenous dose of TCZ 8 mg/kg (n = 12) or saline placebo (n = 6) on day 0. There was a significant reduction in day 4 neutrophil count in TCZ-treated (P < 0Á001) but not placebo-treated subjects ( Fig. 1b and c) . In the TCZ-treated subjects, splitting the groups evenly resulted in six subjects with < 51Á3% relative reduction in day 4 neutrophil count (TCZ-PMN-'high' group) and six subjects with > 51Á3% relative reduction in day 4 neutrophil count (TCZ-PMN-'low' group). No subjects experienced CTC grade 3 or 4 neutropenia. Mean neutrophil counts at day 4 as % baseline were 101Á9% in the placebo group, 68Á3% in the TCZ-PMN-high group and 44Á2% in the TCZ-PMN-low group (P < 0Á001; Fig. 1d ).
Neutrophil function and apoptosis ex vivo
Respiratory burst activity was intact at days 0 and 4 in neutrophils isolated from placebo, TCZ-PMN-low and TCZ-PMNhigh groups; mean peak chemiluminescence did not show and day 4 (post-dose) blood neutrophil counts in placebo-treated subjects (n = 6) and TCZtreated subjects (n = 12). # P < 0Á001. (d) Day 4 neutrophil count, as % day 0 count, in placebo (n = 6), TCZ-PMN-high (n = 6) and TCZ-PMN-low (n = 6) groups. *P < 0Á05, # P < 0Á001 vs. placebo; # P < 0Á001 across three groups. Data shown as mean AE SEM. statistically significant differences between the unprimed groups, or between the TNFa-primed groups (Fig. 2a, d, e) . Rates of phagocytosis of heat-killed S. pneumoniae were also similar in all groups, indicating intact phagocytic activity (Fig. 2b, c, f, g ). Neutrophil survival following 20 h of ex vivo culture was unaffected by TCZ, with apoptosis rates showing no differences between placebo and TCZ groups under either untreated conditions or in the presence of the pro-survival factors GM-CSF or TNFa (Fig. 3) . Cell surface markers of neutrophil activation, including CD11b, CD62L, CD162 and shape change [27] [28] [29] , were likewise unaffected by TCZ in both control and fMLP-stimulated neutrophils (Fig. 4a, b, d-g ). Expression of CD16, a marker expressed on mature neutrophils, and declines on ageing neutrophils [30] , was also unaffected by TCZ (Fig. 4a, c) .
Neutrophil kinetics in vivo
For analysis of the in vivo kinetic data, one subject from the TCZ-PMN-high group was excluded because of external (skin) contamination, which affected the profiling data. The mean (SEM) 45-min blood recovery values of 111 In-labelled neutrophils at day 4 as % total body count were 26Á7 (4Á7) in the placebo group (n = 6), 28Á4 (2Á5) in the TCZ-PMN-high group (n = 5) and 29Á9 (5Á9) in the TCZ-PMN-low group (n = 6) (Fig. 5b ); these were not significantly different, indicating a similar extent of early neutrophil intravascular margination in all groups. Consistent with these data, in TCZ-treated subjects, there were no differences in the distribution of radiolabelled neutrophils in the liver/spleen or pelvic marrow pools 45 min post-re-injection ( Fig. 5c and d) . These data indicate again that However, neutrophil re-distribution to, and uptake in, the pelvic marrow region (which could be used as an index of generalized bone marrow activity) on days 5 and 10 (1 and 6 days following 111 In-labelled neutrophil re-injection, respectively) was considerably lower in the TCZ-PMN-low group ( Fig. 5e and f) ; peak pelvic count, as % day 4 count, on day 5 was 188% in the placebo group, 171% in the TCZ-PMN-high group, and 127% in the TCZ-PMN-low group (P < 0Á001, placebo vs. TCZ-PMN-low), whereas on day 10, it was 180% in the placebo group, 168% in the TCZ-PMN-high group and 132% in the TCZ-PMN-low group (P < 0Á01, placebo vs. TCZ-PMNlow) (Fig. 5h) . This was associated with a clear trend towards higher neutrophil retention in the liver/spleen on days 5 and 10 in the TCZ-PMN-low group (Fig. 5g) , and a correlation between day 10 liver/spleen peak radioactivity and day 4 neutrophil count (r 2 = 0Á38, P < 0Á05; Figure S1c ).
Safety
There were no adverse events leading to study withdrawal. Overall, eight subjects experienced 12 adverse events, and all resolved without sequelae (Table S1 ). Of the nine adverse events in the TCZ-treated subjects, all were mild or moderate in 
DISCUSSION
Anti-IL-6R therapy is an important intervention in inflammatory diseases and has been used successfully in diseases such as rheumatoid arthritis [8, 31] . However, concerns have been raised about its effects on circulating neutrophil numbers and function. This study is the first to assess the pharmacodynamic effects of anti-IL-6R on human neutrophil kinetics in vivo and the first to comprehensively investigate the effects of IL-6R blockade on neutrophil function and apoptosis ex vivo at the expected nadir of blood neutrophil count.
Results of this exploratory study in healthy subjects demonstrated a reduction in neutrophil count 4 days after administration of intravenous TCZ, representing the previously defined neutrophil nadir following TCZ administration [32] . Neutrophil respiratory burst and phagocytic activity remained intact at day 4, suggesting that the capacity of circulating neutrophils to respond to pathogens was unaffected at the time point when TCZ has its greatest effect on the numbers of circulating neutrophils. These data support the clinical trial experience of TCZ use in that no temporal relationship has been demonstrated between reductions in neutrophil counts and risks of serious infection [6] [7] [8] [9] [10] 33] .
Neutrophils were not activated at baseline after TCZ infusion and responded to ex vivo fMLP activation to a similar degree to neutrophils from placebo subjects. Rates of apoptosis in ex vivo culture were also unaffected, suggesting that TCZ does not affect the survival of circulating neutrophils, whose half-life has been estimated in other ex vivo and in vivo labelling studies ranging from several hours to 3Á8 days [34] [35] [36] . The systemic administration of TCZ makes differential functional effects on neutrophils in the circulating and marginated pools unlikely. The current results are consistent with a recent study in healthy subjects and patients with rheumatoid arthritis, which showed no effect of TCZ on ex vivo neutrophil function and rates of apoptosis, when measured 4 and 12 weeks after multiple doses of TCZ [13] .
Assessment of whole body kinetics showed that early neutrophil margination was unaffected by TCZ, with no difference in neutrophil distribution in the blood, liver/spleen and pelvic marrow regions 45 min following re-injection of radiolabelled neutrophils. However, neutrophil trafficking at later times was significantly different in the TCZ-PMN-low group, as demonstrated by reduced neutrophil re-uptake to the pelvic marrow region, with a trend towards higher neutrophil retention in the liver/spleen region on days 5 and 10. These findings indicate that TCZ treatment reduces bone marrow re-uptake of neutrophils, either directly or indirectly via a mechanism involving enhanced retention by the liver and spleen. The former mechanism would be consistent with the previously defined role of IL-6 in the release of neutrophils from the bone marrow compartment in animal models [15, 16] . No subjects experienced CTC grade 3 or 4 neutropenia. However, the significant relative reduction in neutrophil count in TCZ-treated subjects and the differences in neutrophil kinetics in the TCZ-PMN-low group demonstrate the biological effects of TCZ even in the absence of clinically significant neutropenia.
The study has several limitations. The control subjects in our study received saline placebo rather than irrelevant immunoglobulin G (IgG). Previous studies have shown that IL-6-induced STAT-3 phosphorylation is effectively blocked by TCZ but not by IgG in neutrophils from healthy subjects [13] ; nevertheless, we cannot rule out the possibility of nonspecific IgG effects on neutrophils in our results.
Neutrophil release from the bone marrow was not directly examined in the current model, and as such, the effects of TCZ on the release of neutrophils from the bone marrow postmitotic pool in response to a stimulus were not formally assessed. Further investigation is required to demonstrate definitively whether IL-6R blockade affects neutrophil de-margination and/or release of these cells from the bone marrow.
The 45-min blood recovery values of 111 In-labelled neutrophils in the current study were slightly lower than previously demonstrated values. This can indicate a degree of cellular damage during the isolation and radiolabelling process. However, there was no evidence of abnormally high margination of radiolabelled neutrophils to the liver/spleen in the placebo or TCZ groups, which would be observed in the case of cellular damage. In addition, it has been demonstrated previously that the current method of neutrophil isolation and radiolabelling does not cause ex vivo priming or activation of neutrophils, hence allowing neutrophil kinetics to be studied under physiological conditions [26] .
The whole body profiling data demonstrated the effects of TCZ treatment on neutrophil kinetics in vivo, suggesting reduced neutrophil re-uptake to the pelvic bone marrow and some evidence of persistent retention of neutrophils in the liver Inlabelled neutrophils on day 4. ns, nonsignificant across groups. (e-f) Representative longitudinal whole body profiles from a placebo subject and a TCZ-PMN-low subject. Radioactivity from pelvic bone marrow marked by black arrows. (g) Peak liver/spleen radioactivity, normalized to day 4 count, on days 4, 5 and 10 (45 min, 1 day and 6 days post-re-injection, respectively). ns, nonsignificant across placebo groups and across TCZ-PMN-low groups. (h) Peak pelvic bone marrow radioactivity, normalized to day 4 count, on days 4, 5 and 10.
# P < 0Á001, placebo day 4 vs. placebo day 5 and placebo day 4 vs. placebo day 10; # P < 0Á001, placebo day 5 vs. TCZ-PMN-low day 5; † P < 0Á01, placebo day 10 vs. TCZ-PMN-low day 10. Placebo, n = 6; TCZ-PMN-high, n = 5; TCZ-PMN-low, n = 6. Data shown as mean AE SEM.
/ spleen either through a failure of de-margination or enhanced neutrophil destruction at these sites. In humans, healthy neutrophils are removed from the circulation in approximately equal proportions in the liver, spleen and bone marrow. This occurs in a seemingly random and age-independent fashion and does not reflect intravascular apoptosis, which in health is extremely rare. This situation contrasts somewhat to the mouse where aged neutrophils are preferentially removed by the bone marrow, and this involves up-regulation of CXCR4 [37] . Following removal from the circulation neutrophils then undergo apoptosis and are efferocytosed by splenic marginal zone and bone marrow stromal macrophages; this later process has been shown to regulate blood neutrophil levels via the production of G-CSF [38, 39] . While the role of the IL-6/IL-6R axis in these processes is uncertain, marrow sampling was not part of our study.
Overall, these data suggest that the reduction in circulating neutrophils results in a relative rather than absolute neutropenia in patients treated with TCZ. This observation may help explain why no temporal relationship between CTC grade 3 or 4 neutropenia and serious infection has been observed with TCZ treatment. Further work exploring the release of neutrophils from the bone marrow in the presence of TCZ is warranted.
In summary, we have demonstrated for the first time in humans that IL-6R blockade by a single intravenous dose of tocilizumab affects in vivo neutrophil trafficking to the bone marrow without influencing the ex vivo functional capacity, activation and apoptosis of these cells.
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